Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.
Hardy
Thomas A
TA
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. hardyta@lilly.com
Meyers
Adam L
AL
Yu
Jun
J
Shankar
Sudha S
SS
Steinberg
Helmut O
HO
Porksen
Niels K
NK
D001569:Benzodiazepines / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood*; D015309:Glucose Clamp Technique; D006801:Humans; D006943:Hyperglycemia / Q000097:blood; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D000077152:Olanzapine; D012016:Reference Values; D018967:Risperidone / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*
D001569:Benzodiazepines; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D000077152:Olanzapine; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors